Immune Response Following Treatment of Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01147536|
Recruitment Status : Terminated (Sponsor's business decision)
First Posted : June 22, 2010
Last Update Posted : April 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Renal Cell Carcinoma||Biological: HSPPC-96||Phase 2|
A multicenter, randomized, single-blind study to assess patients' immune response following treatment with HSPPC-96 (vitespen, Oncophage®)for resectable renal cell carcinoma (RCC), considered to be at intermediate risk for recurrence given the pathologic tumor stage at time of resection.
The purpose of this study is to determine whether patients exhibit a measurable and durable immune response after multiple administrations of HSPPC-96 during a maximum 15-month time period.
The study consists of two parts: Part 1 with Part 1a (Assessment of Immune Variation)and Part 1b (Assay Standardization), and Part 2 (Immune Monitoring Study).
The study was terminated early with 12 patients enrolled only in Part 1a and Part 1b. Part 2 of the study involved randomization after 8 doses of HSSPC-96. After the 8 doses of HSSPC-96 administered in Part 2, the patients were to be randomized to the Treatment Extension Arm or the Placebo Extension Arm. There were no patients enrolled in Part 2 since the study was terminated early. Therefore, no randomization occurred in the conduct of this study and only a single arm was enrolled.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage)for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
|Experimental: HSPPC-96 treatment||
HSPPC-96 intradermal injection every week for 4 weeks, followed by an injection every other week for 8 weeks
- immunological response in blood sample using ELISPOT assay [ Time Frame: 15 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01147536
|United States, New York|
|Community Care Physicians|
|Albany, New York, United States, 12208|
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Pavillion de Recherche de Hotel Dieu|
|Quebec, Canada, G1R 2J6|
|Principal Investigator:||Louis Lacombe, MD, FRCSC||Service d'Urologie; Centre hospitalier universitaire de Quebec - Hotel-Dieu de Quebec|
|Principal Investigator:||Christopher G Wood, MD, FACS||The University of Texas, MD Anderson Cancer Center|
|Principal Investigator:||Ronald P Kaufman, MD, FACS||Community Care Physicians, PC; The Urological Institute of Northeastern New York|